品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | B126941-5mg | 5mg | 现货 | 701213-36-7 |
Temsavir (BMS-626529) BMS-626529 |
≥98% |
|
|
阿拉丁 | B126941-10mg | 10mg | 现货 | 701213-36-7 |
Temsavir (BMS-626529) BMS-626529 |
≥98% |
|
|
阿拉丁 | B126941-50mg | 50mg | 现货 | 701213-36-7 |
Temsavir (BMS-626529) BMS-626529 |
≥98% |
|
|
阿拉丁 | B425591-1ml | 1ml | 现货 | 701213-36-7 |
BMS-626529 BMS-626529 |
10mM in DMSO |
|
|
麦克林 | T910357-10mg | 10mg | 订前询问 | 701213-36-7 |
Temsavir(BMS-626529) Temsavir(BMS-626529) |
0.98 |
|
|
罗恩 | R029174-50mg | 50mg | 5~7个工作日 | 701213-36-7 |
BMS-626529 BMS-626529 |
98% |
|
|
罗恩 | R029174-5mg | 5mg | 5~7个工作日 | 701213-36-7 |
BMS-626529 BMS-626529 |
98% |
|
|
罗恩 | R029174-10mg | 10mg | 5~7个工作日 | 701213-36-7 |
BMS-626529 BMS-626529 |
98% |
|
|
MARY | MR1310285-10mg | 10mg | 订前咨询 | 701213-36-7 |
BMS-626529 BMS-626529 |
98% |
|
|
MARY | MR1310285-5mg | 5mg | 订前咨询 | 701213-36-7 |
BMS-626529 BMS-626529 |
98% |
|
|
MARY | MR1310285-50mg | 50mg | 订前咨询 | 701213-36-7 |
BMS-626529 BMS-626529 |
98% |
|
|
源叶 | S86260-5mg | 5mg | 期货,请咨询 | 701213-36-7 |
Temsavir (BMS-626529) BMS-626529 |
≥98% |
|
|
源叶 | S86260-10mg | 10mg | 期货,请咨询 | 701213-36-7 |
Temsavir (BMS-626529) BMS-626529 |
≥98% |
|
|
源叶 | S86260-50mg | 50mg | 期货,请咨询 | 701213-36-7 |
Temsavir (BMS-626529) BMS-626529 |
≥98% |
|
|
源叶 | S53606-1ml | 1ml | 期货,请咨询 | 701213-36-7 |
BMS-626529 BMS-626529 |
10mM in DMSO |
|
|
韶远 | SY242178-0.25g | 0.25g | 现货 | 701213-36-7 |
1-(4-苯甲酰基哌嗪-1-基)-2-[4-甲氧基-7-... 1-(4-Benzoylpiperazin-1-yl)-... |
≥95% |
|
|
毕得 | BD304088-10mg | 10mg | 现货 | 701213-36-7 |
1-(4-苯甲酰基哌嗪-1-基)-2-(-甲氧基-7-(... 1-(4-Benzoylpiperazin-1-yl)-... |
98% |
|
|
毕得 | BD304088-50mg | 50mg | 现货 | 701213-36-7 |
1-(4-苯甲酰基哌嗪-1-基)-2-(-甲氧基-7-(... 1-(4-Benzoylpiperazin-1-yl)-... |
98% |
|
|
毕得 | BD304088-100mg | 100mg | 现货 | 701213-36-7 |
1-(4-苯甲酰基哌嗪-1-基)-2-(-甲氧基-7-(... 1-(4-Benzoylpiperazin-1-yl)-... |
98% |
|
|
毕得 | BD304088-25mg | 25mg | 现货 | 701213-36-7 |
1-(4-苯甲酰基哌嗪-1-基)-2-(-甲氧基-7-(... 1-(4-Benzoylpiperazin-1-yl)-... |
98% |
|
|